Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors.
The financing round, led by Bain Capital's private equity group, included investments from Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan.
- Royalty Pharma
- Qatar's sovereign wealth fund
- Canada's national pension plan asset manager
This significant investment highlights the ongoing interest in weight loss drugs, despite past clinical disappointments.
Kailera's Series B round comes almost exactly one year after the startup launched with $400 million and follows Pfizer's announcement to acquire Metsera, another privately held obesity drug developer, for $4.9 billion.
No specific quotes are mentioned in the text.
Author's summary: Kailera Therapeutics raises $600 million.